Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079880677> ?p ?o ?g. }
Showing items 1 to 40 of
40
with 100 items per page.
- W2079880677 endingPage "s84" @default.
- W2079880677 startingPage "s81" @default.
- W2079880677 abstract "Vaskuler endotelyal growth faktor-A’nin (VEGF-A) neovaskuler tip yasa bagli makula dejenerasyonunda (YBMD) neovaskularizasyondan sorumlu en onemli anjiyojenik uyaran oldugu ortaya konulmustur. Bu tespitten sonra ozellikle son 10 yilda neovaskuler tip YBMD tedavisinde onemli gelismeler kaydedilmistir. VEGF-A antagonistleri neovaskuler tip YBMD tedavisinde yaygin olarak kullanilmaya baslamistir. Ranibizumab, neovaskuler YBMD tedavisinde yasal olarak kabul edilen en etkin antagonistidir. ANCHOR ve MARINA calismalarinda intravitreal ranibizumabin aylik uygulandiginda neovaskuler tip YBMD’nin tum tiplerinde etkili oldugu gosterilmistir. Bu iki pilot calismada ilk uc dozu takiben, aylik devam eden enjeksiyonlar ile gorme keskinliginin en iyi sekilde saglandigi gosterilmistir. Ancak, surekli aylik enjeksiyona devam etmek mumkun degildir, bunun yerine lezyon aktivitesine gore hastalarin takibi ve gerektiginde tedavi uygulanabilecek esnek tedavi protokolleri onerilmektedir. Baslangicta ilk 3 ay enjeksiyon genel kabul gormustur. Sonrasinda dikkatli takip ve esnek bir tedavi protokolu gorme kaybini engelleyebilecektir. Bu calismada neovaskuler tip YBMD tedavisinde esnek tedavi protokollerinin sonuclarinin ortaya konulmasi, takip ve tedavi parametrelerinin arastirilmasi amaclanmistir.Anti-vascular endothelial growth factor treatment strategies for neovascular age-related macular degenerationVascular endothelial growth factor-A (VEGF-A) has been implicated as the major angiogenic stimulus responsible for neovascularisation in neovascular age-related macular degeneration. The past decade has been one of great progress for the treatment of neovascular age-related macular degeneration (AMD). Pharmacotherapy against VEGF-A have been introduced to treat neovascular AMD. Ranibizumab at the moment appears to be the most effective approved treatment for neovascular AMD. The benefits of intravitreal ranibizumab apply to all angiographic subtypes of neovascular AMD when the drug is in¬jected at monthly intervals as shown ANCHOR and MARINA study. Treatment initiation with three consecutive monthly injections, followed by continued monthly injections, has provided the best visual acuity outcomes in pivotal cliniveal trials. If continued monthly injections are not feasible after initiation, a flexible strategy appears viable, with monthly monitoring of lesion activity recommended. Initiation regimens of fewer than three injec-tions have not been assessed. Continuous careful monitoring with flexible treatment may help avoid vision loss recurring. The aim of this study was to analyse results of flexible anti-VEGF treatment in neovascular age-related macular degeneration, and to search for parameters with impact on outcome. J. Exp. Clin. Med., 2012; 29:S81-S84" @default.
- W2079880677 created "2016-06-24" @default.
- W2079880677 creator A5065829663 @default.
- W2079880677 date "2012-07-30" @default.
- W2079880677 modified "2023-09-27" @default.
- W2079880677 title "Neovasküler yaşa bağlı makula dejenerasyonunda anti-vasküler endotelyal growth faktör tedavi protokolleri" @default.
- W2079880677 doi "https://doi.org/10.5835/jecm.omu.29.s2.006" @default.
- W2079880677 hasPublicationYear "2012" @default.
- W2079880677 type Work @default.
- W2079880677 sameAs 2079880677 @default.
- W2079880677 citedByCount "0" @default.
- W2079880677 crossrefType "journal-article" @default.
- W2079880677 hasAuthorship W2079880677A5065829663 @default.
- W2079880677 hasBestOaLocation W20798806772 @default.
- W2079880677 hasConcept C556039675 @default.
- W2079880677 hasConcept C71924100 @default.
- W2079880677 hasConceptScore W2079880677C556039675 @default.
- W2079880677 hasConceptScore W2079880677C71924100 @default.
- W2079880677 hasIssue "s2" @default.
- W2079880677 hasLocation W20798806771 @default.
- W2079880677 hasLocation W20798806772 @default.
- W2079880677 hasOpenAccess W2079880677 @default.
- W2079880677 hasPrimaryLocation W20798806771 @default.
- W2079880677 hasRelatedWork W1506200166 @default.
- W2079880677 hasRelatedWork W1995515455 @default.
- W2079880677 hasRelatedWork W2039318446 @default.
- W2079880677 hasRelatedWork W2048182022 @default.
- W2079880677 hasRelatedWork W2080531066 @default.
- W2079880677 hasRelatedWork W2748952813 @default.
- W2079880677 hasRelatedWork W2899084033 @default.
- W2079880677 hasRelatedWork W3031052312 @default.
- W2079880677 hasRelatedWork W3032375762 @default.
- W2079880677 hasRelatedWork W3108674512 @default.
- W2079880677 hasVolume "29" @default.
- W2079880677 isParatext "false" @default.
- W2079880677 isRetracted "false" @default.
- W2079880677 magId "2079880677" @default.
- W2079880677 workType "article" @default.